Duration of drainage was ranged from 4 to 18 days (mean 9.6). Duration of hospital stay ranged from 12 to 65 days (mean 27.9). None had major complications including haemorrhage, haemoptysis, pneumothorax or haemothorax. But, in one tube was dislodged and complicated with subcutaneous emphysema necessitating re-insertion of catheter. PCD was successful in 11 (91.6%) cases, in which 10 (90.9%) had complete clearance of abscess or empyema and 01(9.0%) had partial drainage of abscess. However, 01(8.3%) developed a trapped lung. 01 (8.3%) died due to septicaemia, in which surgery was deferred due to general debility.
major complications. This will be an effective alternative for major surgery with minimal discomfort to the patients and complications. 
Conclusion:
Endotracheal tuberculosis is likely to cause tracheal stenosis, and even atresia, resulting in lung atelectasis. At this time, the strategy for lung reexpansion is mainly bronchoscopic interventionor lungpreserving surgery. In general, bronchoscopic interventional treatment is mainly through the electrocoagulation method to directly open the narrow part of the airway, and then the balloon expands the airway so that air can enter the distal airway and the distal blocked secretions are drained. In this case, the patient bypassed the narrow part of the airway and reached the distal airway through the "proximal airway-Mediastinumdistal airway" pathway that was inadvertently opened. Background and Aims: The hypoxemia during propofol sedation of bronchoscope is a major safety issue in different studies. The impact of the high-flow nasal oxygen (HFNO) to patients undergoing bronchoscopic sedation is unknown. We hypotheses that patients underlying flexible bronchoscopy could benefit from high-flow nasal oxygen to prevent hypoxemia and hypoventilation comparing to current standard care.
Methods: Target controlled infusion of propofol targeted at 2 μg/mL and AE0.2 μg/mL to maintain stable vital signs and sedative levels during bronchoscopy. Patients were randomized to Group 1, HFNO 60 L/min FiO 2 :29% (study group, n = 6), or Group 2, HFNO 30 L/min FiO 2 :29% (study group, n = 6), or Group 3, nasal cannula(NC) 2 L/min(control
